Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Molecular Partners AG (MOLN)

6.655   0.015 (0.23%) 12-07 12:19
Open: 6.655 Pre. Close: 6.64
High: 6.8 Low: 6.655
Volume: 314 Market Cap: 240(M)

Technical analysis

as of: 2022-12-07 4:24:06 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 8.46     One year: 9.89
Support: Support1: 6.47    Support2: 5.98
Resistance: Resistance1: 7.25    Resistance2: 8.46
Pivot: 6.68
Moving Average: MA(5): 6.84     MA(20): 6.64
MA(100): 6.38     MA(250): 12.47
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 45.1     %D(3): 56.2
RSI: RSI(14): 53
52-week: High: 32.04  Low: 5.5
Average Vol(K): 3-Month: 8 (K)  10-Days: 4 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MOLN ] has closed below upper band by 46.8%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.8 - 6.84 6.84 - 6.88
Low: 6.56 - 6.61 6.61 - 6.65
Close: 6.64 - 6.71 6.71 - 6.78

Company Description

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Headline News

Sat, 03 Dec 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Partners AG - MOLN -

Fri, 02 Dec 2022
Molecular Partners AG's (VTX:MOLN) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Yahoo Finance

Mon, 28 Nov 2022
FY2023 EPS Estimates for Molecular Partners AG (NASDAQ:MOLN) Cut by Analyst - MarketBeat

Thu, 03 Nov 2022
2022-11-03 | NDAQ:MOLN | Press Release | Molecular Partners AG - Stockhouse

Sat, 10 Sep 2022
MOLECULAR PARTNERS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Molecular Partners AG and Encourages Investors to Contact the Firm - Business Wire

Mon, 02 May 2022
Moln Store / CASE-REAL - ArchDaily

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 36 (M)
Shares Float 19 (M)
% Held by Insiders 0 (%)
% Held by Institutions 3.1 (%)
Shares Short 13 (K)
Shares Short P.Month 16 (K)

Stock Financials

EPS 3.73
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.73
Profit Margin (%) 62.2
Operating Margin (%) 61.3
Return on Assets (ttm) 31.6
Return on Equity (ttm) 62.4
Qtrly Rev. Growth -33.1
Gross Profit (p.s.) -1.28
Sales Per Share 5.24
EBITDA (p.s.) 3.23
Qtrly Earnings Growth 0
Operating Cash Flow 114 (M)
Levered Free Cash Flow 65 (M)

Stock Valuations

PE Ratio 1.79
PEG Ratio 0
Price to Book value 0.86
Price to Sales 1.28
Price to Cash Flow 2.12

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.